RecruitingNot ApplicableNCT07019597

NESA Neuromodulation Versus Transcutaneous Posterior Tibial Stimulation

Non-invasive NESA Neuromodulation Versus Transcutaneous Posterior Tibial Nerve Stimulation for the Treatment of Overactive Bladder

Sponsor

Daniel David Álamo Arce

Enrollment

25 participants

Start Date

May 1, 2025

Study Type

INTERVENTIONAL

Conditions

Bladder Dysfunction

Summary

Introduction: Overactive bladder (OAB) is a common condition characterized by urinary urgency, frequency, and, in some cases, urge incontinence. Non-invasive neuromodulation has emerged as an effective therapeutic option by modulating the neural pathways involved in bladder control. This approach offers a promising alternative for patients who do not respond to conventional treatments. Objectives: To evaluate the effect of non-invasive NESA neuromodulation compared to posterior tibial stimulation in patients with overactive bladder. compared to posterior tibial stimulation, with same-day exercises and patient education on quality of life, symptoms, discomfort and sleep. day of the session and patient education on quality of life, symptoms, discomfort and sleep. Methods: Twenty-four patients (24 women), aged 38-85 years with overactive bladder will be included in this experimental clinical trial study. Each patient will attend ten sessions two days a week. Patient life quality will be measured using SF-36, sleep quality with the Pittsburgh questionnaire, perception of urinari incontinence (UI) symptoms and patient quality of life with the ICIQ-SF questionnaire. All these variables will be measured before, immediately after the ten sessions and at two months after the end of treatment. Ethic: The study was approved by the ethics committee of the University of Valencia, and all participants will be given an informed consent form.

Eligibility

Inclusion Criteria4

Minimum criteria for a primary diagnosis of overactive bladder who have or have not received active/alternative treatments for this pathology.
Patients with previous pharmacological treatments that have not obtained an adequate clinical response.
Patients whose cognitive abilities are competent to participate in the study and are able to complete the study questionnaires and have given written consent to participate in the study.
Without further contraindications for electrotherapy treatment such as serious use of pacemakers, pregnancy, internal bleeding, poor skin condition (ulcerations, wounds...) and/or phobia of electricity.

Exclusion Criteria12

Presence of urinary fistula.
Infections in the last 12 months.
Haematuria during the trial period.
Pregnancy or plans to become pregnant during the study.
Pathology of the central or peripheral nervous system (multiple sclerosis, Parkinson's disease, etc.).
Uncontrolled diabetes.
Currently treated with Botox injections for the bladder or within the last year.
Current treatment with interstim or currently implanted interstim device.
Bladder outlet obstruction.
Urinary retention.
Treatment with more than two antidepressants and/or multiple benzodiazepines, as well as antiepileptics.
Contraindications for electrotherapy treatment.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICENon-invasive neuromodulation NESA(NNG)

NESA is a non-invasive monitoring device, which emits low frequency (1.3-14.28 Hz, depending on the programme), low intensity (0.1-0.9 mA), low voltage (±3 V) ultra low currents, and therefore imperceptible to the patient. It is based on neuromodulation of the autonomic nervous system.

DEVICENon-invasive Neuromodulation Posterior Tibial (NTPG)

NTPG is an electrotherapy using a device called NEUROTRAC MYOPLUS PRO (brand name) to perform non-invasive TENS-type electrotherapy with biphasic currents.